Compare Microchip Technology Inc. (MCHP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Microchip Technology Inc. trades at $75.75 (market cap $41.01B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Microchip Technology Inc. is far larger — about 4.1× State Street SPDR S&P Biotech ETF's market cap, and Microchip Technology Inc. pays a 2.41% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MCHP | XBI | |
|---|---|---|
Market Cap | $41.01B | $10.11B |
Volume | 9,972,516 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $102.97 | $169.55 |
52-Week Low | $49.02 | $104.99 |
Typical Hold Time | 63 Days | 38 Days |
Enterprise Value | $46.13B | — |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $74.00, down 5.15% over 24 hours amid a bearish technical signal. The company reported a net loss of -$500,000 in 2025, a sharp decline from prior profitability, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion in Ethernet and 48V power portfolios and the completion of the Hailo acquisition, targeting growth in automotive, industrial, and AI-driven data center markets.
Outlook: Strong analyst consensus (69.57% Buy) and a $110.50 price target suggest significant upside potential, driven by AI infrastructure demand and portfolio expansion. Key risks include high valuation multiples, substantial long-term debt of $5.63B, and sensitivity to semiconductor cycle volatility. Earnings recovery in 2026 forecasts is critical for sustaining investor confidence.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
